NO135418B - - Google Patents
Download PDFInfo
- Publication number
- NO135418B NO135418B NO1084/72A NO108472A NO135418B NO 135418 B NO135418 B NO 135418B NO 1084/72 A NO1084/72 A NO 1084/72A NO 108472 A NO108472 A NO 108472A NO 135418 B NO135418 B NO 135418B
- Authority
- NO
- Norway
- Prior art keywords
- general formula
- salt
- indicated above
- ethyl
- melting point
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 claims description 18
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 16
- 229940123208 Biguanide Drugs 0.000 claims description 9
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 9
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 8
- 150000004283 biguanides Chemical class 0.000 claims description 8
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 150000003512 tertiary amines Chemical class 0.000 claims description 8
- 238000009835 boiling Methods 0.000 claims description 7
- OKGXJRGLYVRVNE-UHFFFAOYSA-N diaminomethylidenethiourea Chemical compound NC(N)=NC(N)=S OKGXJRGLYVRVNE-UHFFFAOYSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000012458 free base Substances 0.000 claims description 5
- 150000001412 amines Chemical class 0.000 claims description 4
- 150000001718 carbodiimides Chemical class 0.000 claims description 4
- 150000007522 mineralic acids Chemical class 0.000 claims description 4
- 150000007524 organic acids Chemical class 0.000 claims description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
- 150000003863 ammonium salts Chemical class 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical compound NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 claims description 3
- 229910001385 heavy metal Inorganic materials 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 229910044991 metal oxide Inorganic materials 0.000 claims description 3
- 150000004706 metal oxides Chemical class 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 239000002585 base Substances 0.000 claims description 2
- 235000005985 organic acids Nutrition 0.000 claims description 2
- KGKMETLQCMSQNT-UHFFFAOYSA-N 2-butyl-1-(diaminomethylidene)-3-ethylguanidine;hydrochloride Chemical compound Cl.CCCCN=C(NCC)N=C(N)N KGKMETLQCMSQNT-UHFFFAOYSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000007858 starting material Substances 0.000 claims 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 63
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 54
- 150000001875 compounds Chemical class 0.000 description 30
- 238000002844 melting Methods 0.000 description 30
- 230000008018 melting Effects 0.000 description 30
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 8
- 229910002651 NO3 Inorganic materials 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 229960004111 buformin Drugs 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 6
- 229960004198 guanidine Drugs 0.000 description 6
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 6
- DJAVXQJRIAKWOA-UHFFFAOYSA-N carbonic acid;1-(diaminomethylidene)-3-methylthiourea Chemical compound OC(O)=O.CNC(=S)NC(N)=N DJAVXQJRIAKWOA-UHFFFAOYSA-N 0.000 description 5
- 229960000789 guanidine hydrochloride Drugs 0.000 description 5
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 4
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 3
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 3
- FJMAIXOJSFLKEM-UHFFFAOYSA-N carbonic acid;1-(diaminomethylidene)-3-ethylthiourea Chemical compound OC(O)=O.CCNC(=S)NC(N)=N FJMAIXOJSFLKEM-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 2
- LPXNRJGSIDFGGQ-UHFFFAOYSA-N 1-(diaminomethylidene)-3-propylthiourea Chemical compound CCCNC(=S)N=C(N)N LPXNRJGSIDFGGQ-UHFFFAOYSA-N 0.000 description 2
- VJROPLWGFCORRM-UHFFFAOYSA-N 2-methylbutan-1-amine Chemical compound CCC(C)CN VJROPLWGFCORRM-UHFFFAOYSA-N 0.000 description 2
- KDSNLYIMUZNERS-UHFFFAOYSA-N 2-methylpropanamine Chemical compound CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 2
- WJYIASZWHGOTOU-UHFFFAOYSA-N Heptylamine Chemical compound CCCCCCCN WJYIASZWHGOTOU-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- BMFVGAAISNGQNM-UHFFFAOYSA-N isopentylamine Chemical compound CC(C)CCN BMFVGAAISNGQNM-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
- DPBLXKKOBLCELK-UHFFFAOYSA-N pentan-1-amine Chemical compound CCCCCN DPBLXKKOBLCELK-UHFFFAOYSA-N 0.000 description 2
- 229960003243 phenformin Drugs 0.000 description 2
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- KREOCUNMMFZOOS-UHFFFAOYSA-N 1,3-di(propan-2-yl)thiourea Chemical compound CC(C)NC(S)=NC(C)C KREOCUNMMFZOOS-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- RFGZUHZWZHJFGF-UHFFFAOYSA-N 1-(diaminomethylidene)-2,3-dipropylguanidine;nitric acid Chemical compound O[N+]([O-])=O.CCCNC(NC(N)=N)=NCCC RFGZUHZWZHJFGF-UHFFFAOYSA-N 0.000 description 1
- BVRAQWLCQBWZOE-UHFFFAOYSA-N 1-(diaminomethylidene)-2-methyl-3-propylguanidine;hydrochloride Chemical compound Cl.CCCNC(=NC)N=C(N)N BVRAQWLCQBWZOE-UHFFFAOYSA-N 0.000 description 1
- LLOOCEDSSBQBON-UHFFFAOYSA-N 1-(diaminomethylidene)-3-ethyl-2-heptylguanidine;hydrochloride Chemical compound Cl.CCCCCCCN=C(NCC)N=C(N)N LLOOCEDSSBQBON-UHFFFAOYSA-N 0.000 description 1
- FNMJZTGQHUXSHY-UHFFFAOYSA-N 1-(diaminomethylidene)-3-ethyl-2-methylguanidine;nitric acid Chemical compound O[N+]([O-])=O.CCNC(=NC)N=C(N)N FNMJZTGQHUXSHY-UHFFFAOYSA-N 0.000 description 1
- DXMHLHCOCQTHEF-UHFFFAOYSA-N 1-(diaminomethylidene)-3-heptyl-2-methylguanidine;hydrochloride Chemical compound Cl.CCCCCCCNC(=NC)N=C(N)N DXMHLHCOCQTHEF-UHFFFAOYSA-N 0.000 description 1
- VBWLMIYYNSQZBZ-UHFFFAOYSA-N 1-(diaminomethylidene)-3-hexyl-2-methylguanidine;hydrochloride Chemical compound Cl.CCCCCCNC(=NC)N=C(N)N VBWLMIYYNSQZBZ-UHFFFAOYSA-N 0.000 description 1
- SPLJCDGYZTYQQY-UHFFFAOYSA-N 1-(diaminomethylidene)-3-methylthiourea Chemical compound CNC(=S)NC(N)=N SPLJCDGYZTYQQY-UHFFFAOYSA-N 0.000 description 1
- PCAUSEZGTJUFRH-UHFFFAOYSA-N 1-cyano-3-ethyl-2-methylguanidine Chemical compound CCN=C(NC)NC#N PCAUSEZGTJUFRH-UHFFFAOYSA-N 0.000 description 1
- ULFNAOHBWGRYLW-UHFFFAOYSA-N 1-cyclononylazonane Chemical compound C1CCCCCCCC1N1CCCCCCCC1 ULFNAOHBWGRYLW-UHFFFAOYSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- KREZRKULMRIOKR-UHFFFAOYSA-N 2-butyl-1-(diaminomethylidene)-3-ethylguanidine Chemical compound CCCCN=C(NCC)N=C(N)N KREZRKULMRIOKR-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- IEDBTSYRKOBFMZ-UHFFFAOYSA-N CCCCNC([S+](C)CCCC)=N.Cl Chemical compound CCCCNC([S+](C)CCCC)=N.Cl IEDBTSYRKOBFMZ-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FLVIGYVXZHLUHP-UHFFFAOYSA-N N,N'-diethylthiourea Chemical compound CCNC(=S)NCC FLVIGYVXZHLUHP-UHFFFAOYSA-N 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- XKHACUZPFNGGOQ-UHFFFAOYSA-N [Hg].S=O Chemical compound [Hg].S=O XKHACUZPFNGGOQ-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- VVSVSDQFUZWMHE-UHFFFAOYSA-N carbonic acid;1-(diaminomethylidene)-3-propylthiourea Chemical compound OC(O)=O.CCCNC(=S)NC(N)=N VVSVSDQFUZWMHE-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 150000002168 ethanoic acid esters Chemical class 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229910000464 lead oxide Inorganic materials 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- NQCSXZABSQWSJN-UHFFFAOYSA-N methyl n-(diaminomethylidene)-n'-ethylcarbamimidothioate;hydroiodide Chemical compound I.CCNC(SC)=NC(N)=N NQCSXZABSQWSJN-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- QAOHUQQBIYCWLD-UHFFFAOYSA-N n,n'-dibutylmethanediimine Chemical compound CCCCN=C=NCCCC QAOHUQQBIYCWLD-UHFFFAOYSA-N 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- IOQPZZOEVPZRBK-UHFFFAOYSA-N octan-1-amine Chemical compound CCCCCCCCN IOQPZZOEVPZRBK-UHFFFAOYSA-N 0.000 description 1
- YEXPOXQUZXUXJW-UHFFFAOYSA-N oxolead Chemical compound [Pb]=O YEXPOXQUZXUXJW-UHFFFAOYSA-N 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- BHRZNVHARXXAHW-UHFFFAOYSA-N sec-butylamine Chemical compound CCC(C)N BHRZNVHARXXAHW-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
- C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61C—DENTISTRY; APPARATUS OR METHODS FOR ORAL OR DENTAL HYGIENE
- A61C1/00—Dental machines for boring or cutting ; General features of dental machines or apparatus, e.g. hand-piece design
- A61C1/02—Dental machines for boring or cutting ; General features of dental machines or apparatus, e.g. hand-piece design characterised by the drive of the dental tools
- A61C1/05—Dental machines for boring or cutting ; General features of dental machines or apparatus, e.g. hand-piece design characterised by the drive of the dental tools with turbine drive
- A61C1/057—Dental machines for boring or cutting ; General features of dental machines or apparatus, e.g. hand-piece design characterised by the drive of the dental tools with turbine drive with means for preventing suction effect in turbine after deactivation of the drive air
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dentistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Av stoffgruppen substituerte biguanider anvendes tre forbindelser ved behandling av Diabetes mellitus,, Det er 1-butylbiguanid, l-(3-f enethylbiguanid ("Phenformin") og 1,1-dimethy1-biguanid ("Metformin"). Karakteristisk for de tre nevnte forbindelser er deres lille terapeutiske bredde og deres gastrointestinale uforenelighet. Of the substance group substituted biguanides, three compounds are used in the treatment of diabetes mellitus, They are 1-butylbiguanide, l-(3-f enethylbiguanide ("Phenformin") and 1,1-dimethyl1-biguanide ("Metformin"). Characteristic of the three said compounds are their small therapeutic breadth and their gastrointestinal incompatibility.
Det har nu vist seg at 1,2-substituerte biguanider av den generelle formel: It has now been shown that 1,2-substituted biguanides of the general formula:
hvor R., og R~ hver er en mettet, rettkjedet eller forgrenet hydrocarbongruppe med 1-12 carbonatomer, har en like god eller bedre blodsukkersenkning enn de ovenfor nevnte handels-produkter og overtreffer dem mange ganger i terapeutisk bredde. Således utgjør f.eks. for 1-butylbiguanid LD^Q på mus 346 mg/kg, mens de nye 1,2-biguanider i doser på 2 g/kg tåles uten skade. where R., and R~ are each a saturated, straight-chain or branched hydrocarbon group with 1-12 carbon atoms, have as good or better blood sugar lowering than the above-mentioned commercial products and surpass them many times in therapeutic breadth. Thus, e.g. for 1-butylbiguanide LD^Q in mice 346 mg/kg, while the new 1,2-biguanides in doses of 2 g/kg are tolerated without harm.
Foreliggende oppfinnelse angår således en analogifremgangsmåte ved fremstilling av terapeutisk aktive biguanider av den generelle formel: The present invention thus relates to an analogous method for the production of therapeutically active biguanides of the general formula:
hvor R1 og R2 hver er en mettet, rettkjedet eller forgrenet hydrocarbongruppe med 1-12 carbonatomer. where R1 and R2 are each a saturated, straight-chain or branched hydrocarbon group with 1-12 carbon atoms.
De nye forbindelser av formel I fremstilles ved at: The new compounds of formula I are prepared by:
a) et thiourea av den generelle formel: a) a thiourea of the general formula:
hvor where
R^ og R^ er som ovenfor angitt, i nærvær av et metall eller metalloxyd, eller R^ and R^ are as indicated above, in the presence of a metal or metal oxide, or
et isothiourea av den generelle formel: an isothiourea of the general formula:
hvor where
Rl°g ^2 er som oven^or angitt, i nærvær av et tertiært amin, eller Rl°g ^2 is as indicated above, in the presence of a tertiary amine, or
et carbodiimid av den generelle formel: a carbodiimide of the general formula:
hvor R^ og R^ er som ovenfor angitt, where R^ and R^ are as indicated above,
omsettes med guanidin eller et salt av guanidin, eller reacted with guanidine or a salt of guanidine, or
b) et guanylthiourea av den generelle formel: b) a guanylthiourea of the general formula:
hvor R^ er som ovenfor angitt, eller et salt derav, i nærvær av where R^ is as indicated above, or a salt thereof, in the presence of
et tungmetallsalt og eventuelt i nærvær av et tertiært amin, eller a heavy metal salt and optionally in the presence of a tertiary amine, or
et guanylisothiourea av den generelle formel: a guanylisothiourea of the general formula:
hvor R^ er som ovenfor angitt, eller et salt derav, where R^ is as indicated above, or a salt thereof,
omsettes med et amin av den generelle formel: is reacted with an amine of the general formula:
hvor R^ er som ovenfor angitt, eller where R^ is as indicated above, or
c) et cyanguanidin av den generelle formel: c) a cyanoguanidine of the general formula:
hvor R-^ og R2 er som ovenfor angitt, omsettes med et ammonium- where R-^ and R2 are as indicated above, is reacted with an ammonium
salt i et hoytkokende opplosningsmiddel ved forhoyet tempera- salt in a high-boiling solvent at an elevated temperature
tur , trip,
og at der eventuelt av et ifolge a) til c) erholdt syreaddi-sjonssalt frigjores den frie base av formel I med en sterk base, og/eller eventuelt den frie base overfores til et syreaddi-.sjonssalt med en uorganisk eller organisk syre. and that, where appropriate, from an acid addition salt obtained according to a) to c), the free base of formula I is liberated with a strong base, and/or optionally the free base is transferred to an acid addition salt with an inorganic or organic acid.
Reaksjonene ifolge a) og b) utfores i alminnelighet i opplos-ningsmidler. Som opplosningsmiddel kommer f.eks. i betraktning: alkoholer, som methanol, ethanol, n-propanol, isopropanol eller ethylenglycol; cycliske ethere, som tetrahydrofuran eller dioxan*, hydrocarboner, som nitrobenzen eller anisol; videre dimethylformamid og dimethylsulfoxyd; men også vann. Opplosningsmiddelblandinger kan også anvendes. ;Som metall eller metalloxyd ved omsetningen av et thiourea med guanidin ifolge a) kommer f.eks. Raney-nikkel, blyoxyd og kvikksolvoxyd på tale. Reaksjonstiden avhenger av reaksjonstemperaturen. Temp-eraturen kan varieres vidt. Således kan man arbeide ved værelsetemperatur, men også ved hoyere temperaturer, f.eks. ved 30 - l80°C. ;Reaksjonen av et isothiourea med guanidin ifolge a) utfores i nærvær av et tertiært amin ved forhoyet temperatur, særlig ved 100 - 150°C. ;Med et tertiært amin forståes alle kjente tertiære aminer som f.eks. triethylamin, trimethylamin, ethyldiisopropylamin, azabicyclo-nonan, pyridin, kinolin osv. ;Også ved omsetningen av et guanylthiourea med et amin ifolge ;b) har en tilsetning av tertiært amin vist seg gunstig. ;Som tungmetallsalt ved omsetningen av et guanylthiourea ifolge ;b) kommer f.eks. solvnitrat eller kvikksblv (II)-klorid i betraktning. Reaksjonen lykkes i temperaturområdet fra -50° til +100°C, fortrinnsvis ved -20° til +50°C. ;Når et carbodiimid'skal omsettes med guanidin ifolge a) eller ;et guanylisothiourea med et amin ifolge b), må hoyere temperaturer, fortrinnsvis temperaturer opptil kokepunktet av det anvendte opplosningsmiddel eller opplosningsmiddelblanding anvendes. Ved å gå ut fra carbodiimid kan bare 1,2-disubstituerte biguanider. fremstilles. ;Et cyanguanidin av den generelle formel VIII omsettes ifolge fremgangsmåten under c) med et ammoniumsalt i et hoytkokende opplosningsmiddel ved forhoyet temperatur. Som ammoniumsalt kommer eks-empelvis ammoniumklorid, -nitrat, -sulfat, -fosfat o.s.v. på tale. Som hoytkokende opplosningsmiddel er f.eks. nitrobenzen, anisol, dimethylsulfoxyd, o-diklorbenzen og hexamethylfosforsyretriamid egnet. Omsetningen skjer ved temperaturer over 100°C, fortrinnsvis mellom 110 og 150°C. ;De nye 1,2-substituerte biguanider har en miost like god blod-sukker senkende aktivitet som de kjente 1-substituerte biguanider. De nye forbindelser er imidlertid overlegne over de kjente forbindelser ved at de er mindre giftige. ;Til toxisitetsbestemmelsen ifolge Kårber (L. Ther. Grundlagen der experimentellen Arzneimittelforschung, Wiss. Verlagsgesellschaft Stuttgart (1965), 77 - 79) opploses syreaddisjonssaltene i vann og gies oralt i forskjellige doser til grupper hver på 3 mus. Fem dager efter inngivelse av forbindelsen telles antallet av overlevende dyr. ;I den folgende Tabell er LD^Q-verdien for noen av forbindelsene ifolge oppfinnelsen stillet opp mot LD^Q-verdien for "Phenformin" og 1-butylbiguanid. LD^Q-verdiene refererer seg i hvert tilfelle til den ;Biguanidene av formel I som fremstilles ifolge oppfinn- ;elsen, er således godt tålbare stoffer. På grunn av sine små gastrointestinale bivirkninger er de særlig egnet for behandling av kronisk diabetes. En sammenligning av fremgangsmåteforbind-elsene av formel I med handelspreparatet "Buformin" viser f0eks. ;at l-ethyl-2-n-butylbiguanid-hydroklorid selv ved det fire-dobbelte (800 mg) av den terapeutiske dosering for "Buformin" ;ikke fremkaller noen gastrointestinale bivirkninger hos dia-betikere, mens "Buformin" allerede ved en dose på 200 mg viser gastrointestinale forstyrrelser hos fire av ti pasienter. l-ethyl-2-n-butylbiguanid er således den foretrukne fremgangsmåte-forbindelse. ;De nye virkestoffer eller de farmasoytisk anvendbare salter av disse kan anvendes oralt. Til saltdannelse kan fysiologisk godtag-bare uorganiske eller organiske syrer, som f.eks. saltsyre, hydrogenbromid, salpetersyre, svovelsyre, fosforsyre, methansulfonsyre, p-toluensulfonsyre, nafthalen-1,5-disulfonsyre, eddiksyre, melkesyre, ravsyre, vinsyre, maleinsyre og nikotinsyre, anvendes. ;Konfeksjoneringen av forbindelsene kan skje uten tilsetning eller med de i den galeniske farmasi vanlige tilsetninger, bærere, smakskorrigenser og lignende, og kan f.eks. skje i pulverform, som tabletter, dragser, kapsler, piller, i form av suspensjoner eller oppldsninger. ;Egnede doseenhetsformer som dragéer eller tabletter, inneholder fortrinnsvis 5 - 200 mg av virkestoffet ifolge oppfinnelsen. ;Eksempel 1 ;1. 2- di- isopropylguanid- hydrobromid ;22,9 g (2^-0 mmol) guanidinhydroklorid i 2h0 ml absolutt ethanol tilsettes til en oppldsning av 5? 52 g (2^0 mmol) natrium i 2^-0 ml absolutt ethanol. Det utfelte natriumklorid sentrifugeres, guanidin-opplosningen fradekanteres og tilsettes under omrpring 38, h g ;(2^0 mmol) di-isopropylthiourea og 110 g (500 mmol) gult kvikksolvoxyd. Der omrores i 60 timer, filtreres, tilsettes 6k%- ±g hydrogenbromid inntil pH h og inndampes ved 35°C til ca. 150 ml. ;Det krystallinske råprodukt vaskes med kold ethanol og omkrystalliseres en gang fra varm ethanol. ;Utbytte: 17,6 g 2Q% av det teoretiske. ;Smeltepunkt: 2h7 - 2^8°C. ;Eksempel 2 ;1. 2- diethylbiguanid- hydrobromid ;Forbindelsen fremstilles analogt med eksempel 1 med diethylthio-urea. ;Utbytte: 32% av det teoretiske. ;Smeltepunkt: 20^°C (fra ethanol). ;Eksempel 3 ;1. 2- di- n- butylguanid- hydroklorid ;0,715 g (7,5 mmol) guanidin-hydroklorid, 1,5<*>+ g (10 mmol) di-n-butylcarbodiimid, 5 ml vann og 15 ml methanol oppvarmes i 16 timer under tilbakelop. Efter inndampning blir det oljeaktige residuum tatt opp i 15 ml vann og ekstrahert med 3 x 20 ml ether for å fjerne det som biprodukt dannede 1,2-di-n-butylurea. Den vandige fase tilsettes konsentrert saltsyre inntil pH h og krystalliseres ved inndampning. Råproduktet med smeltepunkt 102 - 105°C er fremdeles for-urenset med guanidin-hydroklorid og små mengder 1,2-di-n-butylurea. Det suspenderes i torr kloroform, det gjenværende guanidin-hydroklorid frafUtreres, kloroformopplosningen inndampes og det faste residuum krystalliseres fra acetonitril. The reactions according to a) and b) are generally carried out in solvents. As a solvent comes e.g. in consideration: alcohols, such as methanol, ethanol, n-propanol, isopropanol or ethylene glycol; cyclic ethers, such as tetrahydrofuran or dioxane*, hydrocarbons, such as nitrobenzene or anisole; further dimethylformamide and dimethylsulfoxide; but also water. Solvent mixtures can also be used. As a metal or metal oxide in the reaction of a thiourea with guanidine according to a) e.g. Raney-nickel, lead oxide and mercury sulfur oxide in question. The reaction time depends on the reaction temperature. The temperature can be varied widely. Thus, you can work at room temperature, but also at higher temperatures, e.g. at 30 - 180°C. ;The reaction of an isothiourea with guanidine according to a) is carried out in the presence of a tertiary amine at an elevated temperature, particularly at 100 - 150°C. A tertiary amine is understood to mean all known tertiary amines such as e.g. triethylamine, trimethylamine, ethyldiisopropylamine, azabicyclononane, pyridine, quinoline, etc. ;Also in the reaction of a guanylthiourea with an amine according to ;b) an addition of a tertiary amine has proven beneficial. ;As a heavy metal salt in the reaction of a guanylthiourea according to ;b) e.g. solvent nitrate or mercury (II) chloride into consideration. The reaction is successful in the temperature range from -50° to +100°C, preferably at -20° to +50°C. When a carbodiimide is to be reacted with guanidine according to a) or a guanylisothiourea with an amine according to b), higher temperatures, preferably temperatures up to the boiling point of the solvent or solvent mixture used, must be used. Starting from carbodiimide, only 1,2-disubstituted biguanides can. is produced. A cyanoguanidine of the general formula VIII is reacted according to the method under c) with an ammonium salt in a high-boiling solvent at an elevated temperature. As ammonium salt, for example, ammonium chloride, -nitrate, -sulphate, -phosphate etc. on speech. As a high-boiling solvent, e.g. nitrobenzene, anisole, dimethylsulfoxyd, o-dichlorobenzene and hexamethylphosphoric acid triamide suitable. The conversion takes place at temperatures above 100°C, preferably between 110 and 150°C. The new 1,2-substituted biguanides have almost as good blood-sugar-lowering activity as the known 1-substituted biguanides. However, the new compounds are superior to the known compounds in that they are less toxic. For the toxicity determination according to Kårber (L. Ther. Grundlagen der experimentellen Arzneimittelforschung, Wiss. Verlagsgesellschaft Stuttgart (1965), 77 - 79) the acid addition salts are dissolved in water and given orally in different doses to groups of 3 mice each. Five days after administration of the compound, the number of surviving animals is counted. In the following table, the LD^Q value for some of the compounds according to the invention is compared to the LD^Q value for "Phenformin" and 1-butylbiguanide. The LD^Q values refer in each case to the Biguanides of formula I which are produced according to the invention are thus well tolerated substances. Because of their minor gastrointestinal side effects, they are particularly suitable for the treatment of chronic diabetes. A comparison of the process compounds of formula I with the commercial preparation "Buformin" shows e.g. that l-ethyl-2-n-butylbiguanide hydrochloride even at four times (800 mg) the therapeutic dosage for "Buformin" does not cause any gastrointestinal side effects in diabetics, while "Buformin" already at a dose of 200 mg shows gastrointestinal disturbances in four out of ten patients. Thus, 1-ethyl-2-n-butylbiguanide is the preferred process compound. The new active substances or the pharmaceutically usable salts thereof can be used orally. For salt formation, only inorganic or organic acids, such as e.g. hydrochloric acid, hydrogen bromide, nitric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalene-1,5-disulfonic acid, acetic acid, lactic acid, succinic acid, tartaric acid, maleic acid and nicotinic acid, are used. The confection of the compounds can take place without addition or with the usual additions, carriers, taste corrections and the like in galenic pharmacy, and can e.g. in powder form, such as tablets, dragees, capsules, pills, in the form of suspensions or solutions. Suitable dosage unit forms such as dragées or tablets preferably contain 5 - 200 mg of the active ingredient according to the invention. ;Example 1 ;1. 2-di-isopropylguanide hydrobromide; 22.9 g (2^-0 mmol) guanidine hydrochloride in 2 h0 ml of absolute ethanol are added to a solution of 5? 52 g (2^0 mmol) sodium in 2^-0 ml absolute ethanol. The precipitated sodium chloride is centrifuged, the guanidine solution is decanted off and 38 g (2^0 mmol) of diisopropylthiourea and 110 g (500 mmol) of yellow mercury solvoxide are added with stirring. Stir for 60 hours, filter, add 6k% ± g hydrogen bromide until pH h and evaporate at 35°C to approx. 150 ml. The crystalline crude product is washed with cold ethanol and recrystallized once from hot ethanol. ;Yield: 17.6 g 2Q% of the theoretical. ;Melting point: 2h7 - 2^8°C. ;Example 2 ;1. 2-diethylbiguanide hydrobromide; The compound is prepared analogously to example 1 with diethylthio-urea. ;Yield: 32% of the theoretical. ;Melting point: 20^°C (from ethanol). ;Example 3 ;1. 2-di-n-butylguanide hydrochloride; 0.715 g (7.5 mmol) guanidine hydrochloride, 1.5<*>+ g (10 mmol) di-n-butylcarbodiimide, 5 ml water and 15 ml methanol are heated in 16 hours during backflow. After evaporation, the oily residue is taken up in 15 ml of water and extracted with 3 x 20 ml of ether to remove the by-product 1,2-di-n-butylurea. Concentrated hydrochloric acid is added to the aqueous phase until pH h and crystallized by evaporation. The crude product with a melting point of 102 - 105°C is still contaminated with guanidine hydrochloride and small amounts of 1,2-di-n-butylurea. It is suspended in dry chloroform, the remaining guanidine hydrochloride is filtered off, the chloroform solution is evaporated and the solid residue is crystallized from acetonitrile.
Utbytte: 0,<1>+2 g 23$ av det teoretiske. Yield: 0.<1>+2 g 23$ of the theoretical.
Smeltepunkt: 131 - 133°C Melting point: 131 - 133°C
Eksempel ^ 4- Example ^ 4-
1. 2- di- n- butylbiguanid- hydroklorid 1. 2-di-n-butylbiguanide hydrochloride
1,88 g (10 mmol) 1,2-di-n-butylthiourea opploses i 10 ml absolutt ethanol og oppvarmes med et overskudd ( h, 7 g) methylklorid i 12 timer i autoklav ved 90°C. Efter avkjoling inndampes til torrhet og det dannede 1,2-di-n-butyl-S-methylisothiourea-hydroklorid tilsettes 0,95 g (10 mmol) guanidin-hydroklorid og 20 ml triethylamin og oppvarmes i autoklav i 6 timer ved" 120°C. Råproduktet inndampes til torrhet og det faste residuum utrores med 3 x 20 ml torr kloroform. 1.88 g (10 mmol) of 1,2-di-n-butylthiourea is dissolved in 10 ml of absolute ethanol and heated with an excess (h, 7 g) of methyl chloride for 12 hours in an autoclave at 90°C. After cooling, it is evaporated to dryness and the 1,2-di-n-butyl-S-methylisothiourea hydrochloride formed is added to 0.95 g (10 mmol) of guanidine hydrochloride and 20 ml of triethylamine and heated in an autoclave for 6 hours at "120° C. The crude product is evaporated to dryness and the solid residue is extracted with 3 x 20 ml of dry chloroform.
Kloroformekstraktene inndampes og det faste residuum omkrystalliseres fra acetonitril. The chloroform extracts are evaporated and the solid residue is recrystallized from acetonitrile.
Utbytte: 1,13 g ^5$ av det teoretiske. Yield: 1.13 g ^5$ of the theoretical.
Smeltepunkt: 131 - 132°C (fra acetonitril). Melting point: 131 - 132°C (from acetonitrile).
Eksempel 5 Example 5
l- ethyl- 2-( 2- methylbutyl)- biguanid- nitrat l- ethyl- 2-( 2- methylbutyl)- biguanide- nitrate
17,7 g (100 mmol) l-ethyl-3-guanylthiourea-carbonat opploses varmt i h00 ml ethanol, tilsettes 19,2 g (220 mmol) 2-methylbutylamin ved 10°C og avkjoles til 0 - 5°C. I lopet av 1 time ved 15°C tilsettes 38 g (220 mmol) solvnitrat i 1<1>+00 ml ethanol og der omrbres i 30 minutter ved værelsetemperatur. Overskudd av sblvioner fjernes som sulfid med hydrogensulfid, og filtratet inndampes til torrhet. Råproduktet omkrystalliseres fra litt vann og derpå fra acetonitril. 17.7 g (100 mmol) of 1-ethyl-3-guanylthiourea carbonate are dissolved hot in 100 ml of ethanol, 19.2 g (220 mmol) of 2-methylbutylamine are added at 10°C and cooled to 0 - 5°C. Over the course of 1 hour at 15°C, 38 g (220 mmol) of solvate nitrate in 1<1>+00 ml of ethanol are added and stirred for 30 minutes at room temperature. Excess sbl ions are removed as sulphide with hydrogen sulphide, and the filtrate is evaporated to dryness. The crude product is recrystallized from a little water and then from acetonitrile.
Utbytte: 8,7 g = 33$ av det teoretiske. Yield: 8.7 g = 33$ of the theoretical.
Smeltepunkt: 133,5 - 13^,5°C Melting point: 133.5 - 13^.5°C
Eksempel 6 Example 6
l- methyl- 2-( 2- methylbutyl)- biguanid- nitrat1 l- methyl- 2-( 2- methylbutyl)- biguanide- nitrate1
Forbindelsen fremstilles analogt med eksempel 5 fra 1-methyl-3-guanylthiourea og 2-methylbutylamin. The compound is prepared analogously to example 5 from 1-methyl-3-guanylthiourea and 2-methylbutylamine.
Utbytte: 51$ av det teoretiske. Dividend: 51$ of the theoretical.
Smeltepunkt: 88-90°C (fra acetonitril). Melting point: 88-90°C (from acetonitrile).
Eksempel 7 Example 7
l- ethyl- 2- n- propylbiguanid- nitrat l- ethyl- 2- n- propyl biguanide nitrate
Forbindelsen fremstilles analogt med eksempel 5 med n-propylamin. The compound is prepared analogously to example 5 with n-propylamine.
Utbytte: 11$ av det teoretiske. Dividend: 11$ of the theoretical.
Smeltepunkt: 13^°C (fra acetonitril). Melting point: 13^°C (from acetonitrile).
Eksempel 8 Example 8
l- ethyl- 2- n- butylbiguanid- nitrat l- ethyl- 2- n- butyl biguanide nitrate
Forbindelsen fremstilles analogt med eksempel 5 med n-butylamin. The compound is prepared analogously to example 5 with n-butylamine.
Utbytte: 28$ av det teoretiske. Dividend: 28$ of the theoretical.
Smeltepunkt: 99°C (fra eddiksyreester/ethanol). Melting point: 99°C (from acetic acid ester/ethanol).
Omkrystallisasjon fra ethanol i nærvær av litt konsentrert saltsyre gir dinitratet, smeltepunkt l6h - 165°C. Recrystallization from ethanol in the presence of slightly concentrated hydrochloric acid gives the dinitrate, melting point l6h - 165°C.
Eksempel 9 Example 9
l- ethyl- 2- sek- butylbiguanid- nitrat l- ethyl- 2- sec- butyl biguanide nitrate
Forbindelsen fremstilles analogt med eksempel 5 med sek-butylamin. The compound is prepared analogously to example 5 with sec-butylamine.
Utbytte: 20$ av det teoretiske. Dividend: 20$ of the theoretical.
Smeltepunkt: 183°C (fra acetonitril). Melting point: 183°C (from acetonitrile).
Eksempel 10 Example 10
l- ethyl- 2- j- butylbiguanid- nitrat l- ethyl- 2- j- butyl biguanide nitrate
Forbindelsen fremstilles analogt med eksempel 5 med iso-butylamin. The compound is prepared analogously to example 5 with iso-butylamine.
Utbytte: 18$ av det teoretiske. Dividend: 18$ of the theoretical.
Smeltepunkt: 138 - 139°C (fra acetonitril). Melting point: 138 - 139°C (from acetonitrile).
Eksempel 11 Example 11
l- ethyl- 2- t- butylbiguanid- nitrat l- ethyl- 2- t-butyl biguanide nitrate
Forbindelsen fremstilles analogt med eksempel 5 med t-butylamin. The compound is prepared analogously to example 5 with t-butylamine.
Utbytte: 35$ av det teoretiske. Dividend: 35$ of the theoretical.
Smeltepunkt: l86°C (fra ethanol). Melting point: l86°C (from ethanol).
Eksempel 12 Example 12
l- ethyl- 2- i- pentylbiguanid- nitrat l- ethyl- 2- i- pentyl biguanide nitrate
Forbindelsen fremstilles analogt med eksempel 5 med iso-pentylamin. The compound is prepared analogously to example 5 with iso-pentylamine.
Utbytte: 13$ av det teoretiske. Dividend: 13$ of the theoretical.
Smeltepunkt: 120 - 122°C (fra acetonitril). Melting point: 120 - 122°C (from acetonitrile).
Eksempel 13 Example 13
1, 2- di- n- propylbiguanid- nitrat 1, 2-di-n-propylbiguanide nitrate
Forbindelsen fremstilles analogt med eksempel 5 fra 1-n-propyl-3-guanylthiourea og n-propylamin. The compound is prepared analogously to example 5 from 1-n-propyl-3-guanylthiourea and n-propylamine.
Utbytte: 52$ av det teoretiske. Dividend: 52$ of the theoretical.
Smeltepunkt: 137°C (fra acetonitril). Melting point: 137°C (from acetonitrile).
Eksempel lh Example lh
l- n- propyl- 2- i- propylbiguanid- nitrat l- n- propyl- 2- i- propyl biguanide nitrate
Forbindelsen fremstilles analogt med eksempel 5 fra 1-n-propyl-3-guanylthiourea og i-propylamin. The compound is prepared analogously to example 5 from 1-n-propyl-3-guanylthiourea and i-propylamine.
Utbytte: 26$ av det teoretiske. Dividend: 26$ of the theoretical.
Smeltepunkt: 178°C (fra ethanol). Melting point: 178°C (from ethanol).
Eksempel 15 Example 15
l- ethyl- 2- n- butylbiguanid- hydroklorid l-ethyl-2-n-butylbiguanide hydrochloride
29,3 g (165 mmol) l-ethyl-3-guanylthiourea-carbonat opp-ldses varmt i 300 ml ethanol og avkjoles til værelsetemperatur. Der tilsettes på en gang 33 ml (330 mmol) n-butylamin og derpå tildryppes i lopet av en halv time ved maksimum 30°C en oppløs-ning av U5 g (165 mmol) sublimat i 150 ml ethanol. Der omrores i 30 minutter ved værelsetemperatur, kvikksdlvsulfidet frasentri-fugeres og den alkoliske opplosning inndampes til sirupkonsistens. 29.3 g (165 mmol) of 1-ethyl-3-guanylthiourea carbonate are dissolved hot in 300 ml of ethanol and cooled to room temperature. 33 ml (330 mmol) of n-butylamine are added at once and then a solution of 5 g (165 mmol) of sublimate in 150 ml of ethanol is added dropwise over the course of half an hour at a maximum of 30°C. It is stirred for 30 minutes at room temperature, the mercuric sulphide is centrifuged and the alcoholic solution is evaporated to syrup consistency.
Der omkrystalliseres under kulltilsetning fra 100 ml kok-ende acetonitril. It is recrystallized under the addition of charcoal from 100 ml of boiling acetonitrile.
Utbytte: 37$ av det teoretiske. Dividend: 37$ of the theoretical.
Smeltepunkt: 132 - 133°C (fra acetonitril). Melting point: 132 - 133°C (from acetonitrile).
Eksempel 16 Example 16
l- ethyl- 2- n- hexylbiguanid- hydroklorid l-ethyl-2-n-hexylbiguanide hydrochloride
17,7 g (100 mmol) l-ethyl-3-guanylthiourea-carbonat opploses varmt i ^00 ml ethanol, tilsettes 22,2 g (220 mmol) n-hexylamin ved 10°C og avkjoles til 0 - 5°C. Ved maksimalt 15°C tilsettes i lopet av en time 38 g (220 mmol) solvnitrat i 1^00 ml'ethanol, og der omrores videre i 30 minutter ved værelsetemperatur. Overskudd av sdlvioner fjernes som solvsulfid med hydrogensulfid, filtratet inndampes til oljekonsistens, opploses i litt vann og påfdres på en soyle med 220 g av en sterkt basisk anionutbytter (ioneutbytter III, Merck AG) i 0H~ -formen. Der elueres med 500 ml vann, inndampes til torrhet og inndampes igjen i nærvær av 100 ml cyclohexan til torrhet, for å fjerne overskudd av n-hexylamin. Den resulterende rene, frie base av l-ethyl-2-n-hexylbiguanid overfores med den beregnede mengde 1 N saltsyre og ved inndampning av den vandige opplosning krystalliserer produktet. 17.7 g (100 mmol) of 1-ethyl-3-guanylthiourea carbonate are dissolved hot in 100 ml of ethanol, 22.2 g (220 mmol) of n-hexylamine are added at 10°C and cooled to 0 - 5°C. At a maximum of 15°C, 38 g (220 mmol) of solvnitrate in 1.00 ml of ethanol are added over the course of one hour, and the mixture is stirred for 30 minutes at room temperature. Excess sodium ions are removed as sol sulphide with hydrogen sulphide, the filtrate is evaporated to an oil consistency, dissolved in a little water and applied to a column with 220 g of a strongly basic anion exchanger (ion exchanger III, Merck AG) in the 0H~ form. Elute with 500 ml of water, evaporate to dryness and evaporate again in the presence of 100 ml of cyclohexane to dryness, to remove excess n-hexylamine. The resulting pure, free base of l-ethyl-2-n-hexylbiguanide is treated with the calculated amount of 1 N hydrochloric acid and upon evaporation of the aqueous solution the product crystallizes.
Utbytte: 23$ av det teoretiske. Dividend: 23$ of the theoretical.
Smeltepunkt: 12^+ - 125°C (fra acetonitril). Melting point: 12^+ - 125°C (from acetonitrile).
Eksempel 17 Example 17
1- methyl- 2- n- propylbiguanid- hydroklorid Forbindelsen fremstilles analogt med eksempel 16 fra 1-methyl-3-guanylthiourea-carbonat og n-propylamin. 1-methyl-2-n-propylbiguanide hydrochloride The compound is prepared analogously to example 16 from 1-methyl-3-guanylthiourea carbonate and n-propylamine.
Utbytte: 29$ av det teoretiske. Dividend: 29$ of the theoretical.
Smeltepunkt: 178 - 179°C (fra ethanol). Melting point: 178 - 179°C (from ethanol).
Eksempel 18 Example 18
l- methyl- 2- n- butylbiguani. d- hydroklorid l-methyl-2-n-butyl biguanie. d-hydrochloride
Forbindelsen fremstilles analogt med eksempel 16 fra 1-methyl-3-guanylthiourea-carbonat og n-butylamin. The compound is prepared analogously to example 16 from 1-methyl-3-guanylthiourea carbonate and n-butylamine.
Utbytte: 70$ av det teoretiske. Dividend: 70$ of the theoretical.
Smeltepunkt: 131+°C (fra isopropanol). Melting point: 131+°C (from isopropanol).
Eksempel 19 Example 19
1- methyl- 2- n- hexylbiguanid- hydroklorid 1- methyl- 2- n- hexylbiguanide hydrochloride
Forbindelsen fremstilles analogt med eksempel 16 fra 1-methyl-3-gu.anylthiourea-carbonat og n-hexylamin. The compound is prepared analogously to example 16 from 1-methyl-3-guanylthiourea carbonate and n-hexylamine.
Utbytte: 13$ av det teoretiske. Dividend: 13$ of the theoretical.
Smeltepunkt: 112 - 113°C (fra acetonitril). Melting point: 112 - 113°C (from acetonitrile).
Eksempel 20 Example 20
l- ethyl- 2- isopropylbiguanid- hydro. iodid l- ethyl- 2- isopropyl biguanide- hydro. iodide
9,2 g (30 mmol) 2-methyl-l-ethyl-3-guanylisothiourea-hydro-jodid omrores i 30 ml vann og 11,8 g (200 mmol) isopropylamin i J+8 timer ved 30°C og derpå i 2 timer ved koketemperaturen. Overskudd av isopropylamin, methylmercaptan og vann avsuges. Til det oljeaktige residuum tilsettes 2 ml konsentrert vandig natriumjodidopplosning og derpå vann inntil der dannes en klar opplosning. Produktet krystalliserer ved henstand i en isboks og omkrystalliseres fra aceton-bensin. 9.2 g (30 mmol) of 2-methyl-1-ethyl-3-guanylisothiourea hydro-iodide is stirred in 30 ml of water and 11.8 g (200 mmol) of isopropylamine for J+8 hours at 30°C and then in 2 hours at the boiling temperature. Excess isopropylamine, methyl mercaptan and water are extracted. To the oily residue, add 2 ml of concentrated aqueous sodium iodide solution and then water until a clear solution is formed. The product crystallizes on standing in an icebox and is recrystallized from acetone-gasoline.
Utbytte: 3,05 g = 32$ av det teoretiske. Yield: 3.05 g = 32$ of the theoretical.
Smeltepunkt: I67 - 168°C. Melting point: I67 - 168°C.
Eksempel 21 Example 21
l- methyl- 2- ethylbiguanid- nitrat l- methyl- 2- ethylbiguanide nitrate
2,52 g (20 mmol) l-methyl-2-ethyl-3-cyanguanidin, 1,76 g (22 mmol) ammoniumnitrat og 25 mg p-toluensulfonsyre oppvarmes under omroring i 15 ml torr nitrobenzen i h8 timer ved 130°C. Den avkjolte opplosning utrystes med 2 x 25 ml vann. De for-enede vannfaser utrystes med ether for å fjerne medtrukket nitrobenzen. Vannfasen inndampes til torrhet, og den dannede olje opploses i litt varm ethanol. Efter flere dagers henstand ved værelsetemperatur krystalliserer l-methyl-2-ethylbiguanid-nitrat. 2.52 g (20 mmol) of 1-methyl-2-ethyl-3-cyanoguanidine, 1.76 g (22 mmol) of ammonium nitrate and 25 mg of p-toluenesulfonic acid are heated with stirring in 15 ml of dry nitrobenzene for 8 hours at 130°C . The cooled solution is shaken with 2 x 25 ml of water. The combined aqueous phases are shaken with ether to remove entrained nitrobenzene. The water phase is evaporated to dryness, and the oil formed is dissolved in slightly warm ethanol. After standing for several days at room temperature, 1-methyl-2-ethylbiguanide nitrate crystallizes.
Utbytte: 0,9 = 22$ av det teoretiske. Yield: 0.9 = 22$ of the theoretical.
Smeltepunkt: lhO°C (fra methanol). Melting point: lhO°C (from methanol).
Eksempel 22 Example 22
l- ethyl- 2- n- heptylbiguanid- hydroklorid 1-ethyl-2-n-heptylbiguanide hydrochloride
Forbindelsen fremstilles analogt med eksempel 16 med n-heptylamin. The compound is prepared analogously to example 16 with n-heptylamine.
Utbytte: 57$ av det teoretiske. Dividend: 57$ of the theoretical.
Smeltepunkt: 122 - 123°C (fra acetonitril). Melting point: 122 - 123°C (from acetonitrile).
Eksempel 23 Example 23
l- methyl- 2- n- heptylbiguanid- hydroklorid Forbindelsen fremstilles analogt med eksempel 16 fra 1-methyl-3-guanylthiourea-carbonat og n-heptylamin. 1-methyl-2-n-heptylbiguanide hydrochloride The compound is prepared analogously to example 16 from 1-methyl-3-guanylthiourea carbonate and n-heptylamine.
Utbytte: 65$ av det teoretiske. Dividend: 65$ of the theoretical.
Smeltepunkt: 111 - 112°C (fra acetonitril). Melting point: 111 - 112°C (from acetonitrile).
Eksempel 2k Example 2k
l- ethyl- 2- n- pentylbiguanid- hydroklorid l-ethyl-2-n-pentylbiguanide hydrochloride
Forbindelsen fremstilles analogt med eksempel 16 med n-pentylamin. The compound is prepared analogously to example 16 with n-pentylamine.
Utbytte: 15$ av det teoretiske. Dividend: 15$ of the theoretical.
Smeltepunkt: 120 - 121°C (fra acetonitril). Melting point: 120 - 121°C (from acetonitrile).
Eksempel 25 Example 25
l- methyl- 2- n- pentylbiguanid- hydroklorid Forbindelsen fremstilles analogt med eksempel 16 fra 1- l-methyl-2-n-pentylbiguanide hydrochloride The compound is prepared analogously to example 16 from 1-
Utbytte: 30$ av det teoretiske. Dividend: 30$ of the theoretical.
Smeltepunkt: 117 - ll8°C (fra acetonitril:ethanol = 5:1). Eksempel 26 Melting point: 117 - 118°C (from acetonitrile:ethanol = 5:1). Example 26
l- ethyl- 2- n- octylbiguanid- hydroklorid l-ethyl-2-n-octylbiguanide hydrochloride
Forbindelsen fremstilles analogt med eksempel 16 med n-octylamin. The compound is prepared analogously to example 16 with n-octylamine.
Utbytte: 35$ av det teoretiske. Dividend: 35$ of the theoretical.
Smeltepunkt: 115 - 116°C (fra acetonitril). Melting point: 115 - 116°C (from acetonitrile).
Eksempel 27 Example 27
l- n- propyl- 2- n- butylbiguariid- nitrat l- n- propyl- 2- n- butyl biguariide nitrate
Forbindelsen fremstilles analogt med eksempel 5 fra 1-n-propyl-3-guanylthiourea-carbonat og n-butylamin. The compound is prepared analogously to example 5 from 1-n-propyl-3-guanylthiourea carbonate and n-butylamine.
Utbytte: 21$ av det teoretiske. Dividend: 21$ of the theoretical.
Smeltepunkt: 122 - 123°C (fra acetonitril). Melting point: 122 - 123°C (from acetonitrile).
l- methyl- 2- i- propylbiguanid- nitrat l- methyl- 2- i- propyl biguanide nitrate
Forbindelsen fremstilles analogt med eksempel 5 fra 1-methyl-3-guanylthiourea-carbonat og i-propylamin. The compound is prepared analogously to example 5 from 1-methyl-3-guanylthiourea carbonate and i-propylamine.
Utbytte: ^8$ av det teoretiske. Yield: ^8$ of the theoretical.
Smeltepunkt: 137 - 138°C (fra acetonitril:isopropanol = 70:30). Melting point: 137 - 138°C (from acetonitrile:isopropanol = 70:30).
Claims (2)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19712117015 DE2117015A1 (en) | 1971-04-02 | 1971-04-02 | 1,2-biguanides |
Publications (2)
Publication Number | Publication Date |
---|---|
NO135418B true NO135418B (en) | 1976-12-27 |
NO135418C NO135418C (en) | 1977-04-05 |
Family
ID=5804148
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO1084/72A NO135418C (en) | 1971-04-02 | 1972-03-29 |
Country Status (19)
Country | Link |
---|---|
AR (3) | AR194360A1 (en) |
AT (4) | AT317239B (en) |
AU (1) | AU468307B2 (en) |
BE (1) | BE781590A (en) |
CA (1) | CA988084A (en) |
CH (1) | CH579534A5 (en) |
CS (3) | CS161936B2 (en) |
DD (1) | DD95228A5 (en) |
DE (1) | DE2117015A1 (en) |
DK (1) | DK129651B (en) |
ES (1) | ES401124A1 (en) |
FR (1) | FR2132396B1 (en) |
GB (1) | GB1386130A (en) |
HU (1) | HU162902B (en) |
NL (1) | NL7204493A (en) |
NO (1) | NO135418C (en) |
SE (1) | SE377332B (en) |
SU (4) | SU535903A3 (en) |
ZA (1) | ZA722183B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102008007314A1 (en) | 2008-02-02 | 2009-08-06 | Merck Patent Gmbh | Process for the preparation of 3,6-dihydro-1,3,5-triazine derivatives |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR940304A (en) * | 1946-01-07 | 1948-12-09 | Ici Ltd | Manufacturing process for biguanide derivatives |
-
1971
- 1971-04-02 DE DE19712117015 patent/DE2117015A1/en not_active Withdrawn
-
1972
- 1972-03-15 CS CS6963*A patent/CS161936B2/cs unknown
- 1972-03-15 CS CS6964*A patent/CS161937B2/cs unknown
- 1972-03-15 CS CS1724A patent/CS161935B2/cs unknown
- 1972-03-22 DK DK134572AA patent/DK129651B/en unknown
- 1972-03-23 ES ES401124A patent/ES401124A1/en not_active Expired
- 1972-03-27 GB GB1416272A patent/GB1386130A/en not_active Expired
- 1972-03-27 CH CH454672A patent/CH579534A5/xx not_active IP Right Cessation
- 1972-03-29 NO NO1084/72A patent/NO135418C/no unknown
- 1972-03-29 AR AR241248A patent/AR194360A1/en active
- 1972-03-29 SE SE7204127A patent/SE377332B/xx unknown
- 1972-03-30 HU HUSC383A patent/HU162902B/hu unknown
- 1972-03-30 AU AU40661/72A patent/AU468307B2/en not_active Expired
- 1972-03-30 DD DD161938A patent/DD95228A5/xx unknown
- 1972-03-30 ZA ZA722183A patent/ZA722183B/en unknown
- 1972-03-30 AT AT00784/73A patent/AT317239B/en not_active IP Right Cessation
- 1972-03-30 AT AT279272A patent/AT313301B/en not_active IP Right Cessation
- 1972-03-30 AT AT00786/73A patent/AT321318B/en not_active IP Right Cessation
- 1972-03-30 AT AT00785/73A patent/AT317240B/en not_active IP Right Cessation
- 1972-03-31 BE BE781590A patent/BE781590A/en unknown
- 1972-03-31 SU SU1767915A patent/SU535903A3/en active
- 1972-03-31 SU SU1907667A patent/SU472501A3/en active
- 1972-03-31 SU SU1907668A patent/SU493959A3/en active
- 1972-03-31 SU SU1907665A patent/SU465784A3/en active
- 1972-04-04 CA CA138,838A patent/CA988084A/en not_active Expired
- 1972-04-04 FR FR7211727A patent/FR2132396B1/fr not_active Expired
- 1972-04-04 NL NL7204493A patent/NL7204493A/xx not_active Application Discontinuation
- 1972-11-13 AR AR245079A patent/AR194285A1/en active
- 1972-11-13 AR AR245080A patent/AR192485A1/en active
Also Published As
Publication number | Publication date |
---|---|
AR194360A1 (en) | 1973-07-13 |
CA988084A (en) | 1976-04-27 |
BE781590A (en) | 1972-10-02 |
FR2132396A1 (en) | 1972-11-17 |
AT317239B (en) | 1974-08-26 |
CS161936B2 (en) | 1975-06-10 |
CS161935B2 (en) | 1975-06-10 |
ZA722183B (en) | 1972-12-27 |
GB1386130A (en) | 1975-03-05 |
SU465784A3 (en) | 1975-03-30 |
SU535903A3 (en) | 1976-11-15 |
DK129651B (en) | 1974-11-04 |
SE377332B (en) | 1975-06-30 |
CS161937B2 (en) | 1975-06-10 |
AR194285A1 (en) | 1973-06-29 |
HU162902B (en) | 1973-04-28 |
AU468307B2 (en) | 1973-10-04 |
DK129651C (en) | 1975-04-07 |
AT321318B (en) | 1975-03-25 |
AT313301B (en) | 1974-02-11 |
SU472501A3 (en) | 1975-05-30 |
AT317240B (en) | 1974-08-26 |
DE2117015A1 (en) | 1972-10-26 |
DD95228A5 (en) | 1973-01-20 |
NO135418C (en) | 1977-04-05 |
SU493959A3 (en) | 1975-11-28 |
ES401124A1 (en) | 1975-02-16 |
AU4066172A (en) | 1973-10-04 |
AR192485A1 (en) | 1973-02-21 |
CH579534A5 (en) | 1976-09-15 |
NL7204493A (en) | 1972-10-04 |
FR2132396B1 (en) | 1975-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3960949A (en) | 1,2-Biguanides | |
SE435837B (en) | 4-AMINO-3-CHINOLINE CARBOXYLIC ACIDS AND ITS ESSENTIALS WITH ANTI-SECRETARY AND ANTI-ULCEROS ACTIVITY | |
NO127359B (en) | ||
EP0004532B1 (en) | 1-aryloxy-3-nitratoalkylamino-2-propanols, process for their preparation and pharmaceutical compositions | |
DK159114B (en) | BENZYLDIHYDROFUROPYRIDINE DERIVATIVES AND PREPARATIONS CONTAINING THESE COMPOUNDS | |
IE43508B1 (en) | Aloxypyridyl amines | |
US4324787A (en) | 2-Oxo-1-pyrrolidineacetic acid compounds and their medicinal use | |
NO803266L (en) | ALKYLURINE INGREDIENT DERIVATIVES FOR THE TREATMENT OF DISEASES IN THE FAT SHIFT, FREMG.M. FOR YOU, THEY USE. IN PHARMACEUTICALS FOR TREATMENT. OF FATHER SHIFT PERSONS, BODY. Holds. THESE, AND FORWARD. FOREVER. OF THE MEDICINAL PRODUCTS | |
CH649995A5 (en) | PIPERAZINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS. | |
JPH01131156A (en) | Piperidine derivative | |
US2951843A (en) | Tetrahydrosoquinoline biguanides | |
DE3216843C2 (en) | 3-Thiomethyl-pyridine derivatives, processes for their preparation and pharmaceuticals containing these compounds | |
NL7908287A (en) | TRIAZINONS. | |
NO135418B (en) | ||
US4515806A (en) | Furan derivatives and addition salts thereof pharmaceutical compositions and the therapeutical applications thereof | |
US4281004A (en) | Phenylguanidine therapeutic agents | |
EP0506903A1 (en) | 4-acetoxy-piperidine derivatives, process for their preparation and use as a muscarinic m3-receptor antagonist | |
EP0007525A1 (en) | 2-(4-Aminopiperidino)-3.4-dihydroquinoline derivatives, processes for their preparation, pharmaceutical compositions containing them and their use | |
US4224327A (en) | 4-Pyrimidyl sulfides for the treatment of gastric ulcers | |
DE1695855B2 (en) | 4- (5-Isobutyl-2-pyrimidinyl) sulfonamidophenylacetic acid (2-methoxy-5-chloroanilide) and its salts with physiologically compatible bases | |
NZ208056A (en) | Pyrimidine-thioalkyl-pyridines and pharmaceutical compositions | |
US3031455A (en) | 1-phenethyl-4-piperidyl carbamates | |
US3973017A (en) | Imidazothiazines, derivatives and analogues thereof | |
EP0202461A1 (en) | Substituted derivatives of 2-(N-alkenyl-N-phenyl-amino) imidazoline, their acid addition salts, medicaments containing them and process for their preparation | |
EP0001266B1 (en) | Substituted 2-aminomethylphenyl sulfamates, process for preparing, and pharmaceutical compositions containing the same |